



benefitNEWS

## New Generic Alternatives Offer Promise for Pharmacy Plans

A series of high cost and high volume brand name medications are scheduled to come off patent and be available on a generic basis over the next six to twelve months. This includes the block-buster drug, Nexium, which generates in excess of \$6 billion in annual revenues for manufacturer AstraZeneca. Below is a roster of the major medications coming off patent and the anticipated date when a new generic alternative will be available. The availability of generic alternatives from single-source brand medications offers promise to employers and plan sponsors since generic medications tend to cost measurably less than their brand counter-parts.

<b>Brand Name (with Generic descriptor)</b>	<b>Manufacturer</b>	<b>Therapeutic Use(s)</b>	<b>Estimated U.S. Sales*</b>	<b>Anticipated Generic Availability</b>
Advicor (niacin/lovastatin)	AbbVie	Hyperlipidemia	\$42 million	Second Half (H2) 2014
Asacol (mesalamine)	Warner Chilcott	Ulcerative Colitis	\$460 million	H2 2014
Diovan (valsartan)	Novartis	Hypertension; Heart Failure; Reduction of Cardiovascular Mortality after Myocardial Infarction	\$2.2 billion	H2 2014
Valcyte (valganciclovir hydrochloride)	Roche	Cytomegalovirus (CMV) Disease and Infection; CMV Retinitis	\$195 million	H2 2014
Viracept (nelfinavir mesylate)	ViiV Healthcare	HIV	\$51 million	H2 2014
Orapred ODT (prednisolone sodium phosphate)	Shionogi Pharma	Asthma; Atopic Dermatitis; Allergic Rhinitis	\$33 million	H2 2014
Nexium (esomeprazole magnesium)	AstraZeneca	Gastroesophageal Reflux Disease; Ulcers; Hypersecretory Conditions; H. pylori Eradication	\$6.1 billion	H2 2014
Oxycontin (oxycodone hydrochloride ER)	Purdue	Moderate to Severe Pain	\$2.5 billion	H2 2014
Invega (paliperidone ER)	Janssen	Schizophrenia; Schizoaffective Disorder	\$424 million	H2 2014
Vivelle-Dot (estradiol transdermal patch)	Novartis	Symptoms Associated with Menopause	\$240 million	H2 2014
Fosrenol (lanthanum carbonate)	Shire	Hyperphosphatemia Associated With Chronic Kidney Disease	\$95 million	H2 2014
Exalgo (hydromorphone hydrochloride ER)	Mallinckrodt	Moderate to Severe Pain	\$147 million	H2 2014

Actonel (risedronate sodium)	Warner Chilcott	Osteoporosis Prophylaxis & Treatment; Paget's Disease	\$1 billion	June 2014
Nasonex (mometasone furoate)	Schering/Merck	Seasonal & Perennial Allergic Rhinitis; Nasal Polyps	\$1.1 billion	July 2014
Lumigan (bimatoprost)	Allergan	Glaucoma; Ocular Hypertension	\$367 million	Aug. 2014
Renagel (sevelamer hydrochloride)	Genzyme	Hyperphosphatemia Associated with Chronic Kidney Disease	\$199 million	Sept. 2014
Exforge (amlodipine/valsartan)	Novartis	Hypertension	\$263 million	Oct. 2014
Exforge HCT (amlodipine/valsartan/hydrochlorothiazide)	Novartis	Hypertension	\$93 million	Oct. 2014
Celebrex (celecoxib)	Pfizer	Acute Pain & Primary Dysmenorrhea; Osteoarthritis; Rheumatoid Arthritis; Ankylosing Spondylitis	\$2.2 billion	Dec. 2014
Intuniv (guanfacine hydrochloride ER)	Shire	Attention Deficit and Hyperactivity Disorder	\$475 million	Dec. 2014
Copaxone (glatiramer acetate)	Teva	Multiple Sclerosis	\$3.7 billion	Q1 2015
Baraclude (entecavir)	Bristol Myers Squibb	Hepatitis B	\$314 million	Feb. 2015
Tarka (trandolapril/verapamil hydrochloride)	AbbVie	Hypertension	\$29 million	Feb. 2015
Welchol (colesevelam hydrochloride)	Daiichi Sankyo	Primary Hyperlipidemia; Type 2 Diabetes Mellitus	\$574 million	March 2015

Conner Strong & Buckelew regularly monitors product movement and potential cost shifts so we can help clients better plan for changes in design and utilization. If you have any questions with the matrix above, please contact your Conner Strong & Buckelew account representative.



[connerstrong.com](http://connerstrong.com)



877-861-3220



[news@connerstrong.com](mailto:news@connerstrong.com)



[Change My Preferences](#)

**CONNER  
STRONG &  
BUCKELEW**

INSURANCE | RISK MANAGEMENT | EMPLOYEE BENEFITS

[in](#)

[Click here to change your email preferences or unsubscribe from all communication.](#)